23 stories mentioning VRTXUpdated 18d ago
Every FINWIRES story that references VRTX, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $567.79, according to analysts polled by FactSet.Price: $550.70, Change: $+3.05, Percent Change: +0.56%
Vertex Pharmaceuticals (VRTX) has completed its acquisition of Crinetics Pharmaceuticals (CRNX), Vertex said on Tuesday.Following the acquisition's closing, Jonathan Poole will take over Vertex's chief financial officer role, effective Jan. 1, Vertex said. Poole currently serves as Vertex's senior vice president for finance, the company said.Charles Wagner, chief operating and financial officer of Vertex, will expand his COO role to head Crinetics' integration, effective immediately, Vertex said.Price: $549.07, Change: $+4.55, Percent Change: +0.83%
Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provide a net positive risk-reward profile for the company, RBC Capital Markets said in a Wednesday note.The company is expected to present results from its phase 1 study of VX-828 in patients with cystic fibrosis in H2, with a positive readout potentially strengthening its competitive advantage in the space, RBC analysts said.Favorable data will likely result in modest upside, while unfavorable data will likely lead to little downside, the analysts added.Meanwhile, approval by the US Food and Drug Administration for Vertex's povetacicept in immunoglobulin A nephropathy, with a PDUFA date of Nov. 30, 2026, is likely due to strong interim phase 3 results, the analysts said.They said that the drug's differentiated profile could make it the preferred choice of most doctors.With Sionna Therapeutics (SION) failing to demonstrate significant sweat chloride improvements as an add-on to Trikafta, one of the more significant overhangs on Vertex's stock has been removed, according to the note.RBC's rating on the company's stock is outperform with a price target of $570.Price: $528.18, Change: $-1.47, Percent Change: -0.28%
Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $563.21, according to analysts polled by FactSet.Price: $484.39, Change: $+5.69, Percent Change: +1.19%
Vertex Pharmaceuticals (VRTX) remains well positioned heading into the second half of 2026 as several pipeline catalysts approach, while upcoming competitor cystic fibrosis data is unlikely to materially affect its outlook, UBS Securities said in a note Tuesday.The investment firm said expectations around the competitive threat have already moderated, noting Vertex's once-daily Alyftrek has shown strong efficacy and that the rival study's narrower patient population may limit its read-through to Vertex.UBS said it remains most optimistic about phase III data for inaxaplin in APOL1-mediated kidney disease expected in early 2027, saying positive results could position Vertex as the first company to market in the indication and further expand its nephrology franchise.It also highlighted Phase II data expected this fall in APOL1-mediated kidney disease patients with Type 2 diabetes or moderate proteinuria, a population that could expand the drug's addressable market by 50% to 100%.UBS has a buy rating on the stock with a price target of $585.Price: $480.04, Change: $+9.32, Percent Change: +1.98%
Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength of its core business and pipeline, RBC Capital Markets said in a note emailed Tuesday.The analysts said the stock could benefit once the Sionna Therapeutics (SION) data overhang clears, with upcoming catalysts including the launch of new products, the expected closing of the Crinetics Pharmaceuticals (CRNX) deal, and additional pipeline readouts.The stock does not fully reflect the potential upside from pipeline opportunities, including kidney programs, expansion of povetacicept into autoimmune diseases such as IgA nephropathy and generalized myasthenia gravis, and the longer-term potential of suzetrigine in chronic pain, the analysts added."We believe that given Vertex's strong core revenue, a pipeline that is increasingly becoming more mature, and with optionality to further diversify pipeline with external [business development,] shares should command a higher valuation," the analysts said.RBC lowered its price target on Vertex Pharmaceuticals to $570 from $577 and kept its outperform rating on the stock.Price: $477.03, Change: $+6.30, Percent Change: +1.34%
Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $558.17, according to analysts polled by FactSet.
Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $555, according to analysts polled by FactSet.Price: $483.16, Change: $-2.23, Percent Change: -0.46%
Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $5Price: $485.78, Change: $-12.65, Percent Change: -2.54%
Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday.As of July 6, the NYSE Arca Pharmaceutical Index has gained 11% and the Nasdaq Biotechnology Index has added 18%, compared with a 10% gain for the S&P 500 Index, with recent stock performance driven more by changes in valuation multiples than by earnings estimate revisions, the investment bank said.Morgan Stanley said its US Equity Strategy team expects the sector to benefit from broader market leadership. Biotech remains one of the most rate-sensitive sectors, and historically, the sector has delivered nearly 20% annualized returns during falling-rate environments, according to the note.In addition, merger and acquisition activity remains healthy, with several $5 billion to $10 billion deals recently announced, including AbbVie (ABBV) purchasing Apogee (APGE), and Vertex Pharmaceuticals (VRTX) buying Crinetics Pharmaceuticals (CRNX), the investment bank said.Morgan Stanley adjusted its price targets on Biogen (BIIB) to $222 from $224, Amgen (AMGN) to $333 from $340, Gilead Sciences (GILD) to $166 from $168, AbbVie to $279 from $278, Moderna (MRNA) to $39 from $33, BioNTech (BNTX) to $119 from $126, Regeneron Pharmaceuticals (REGN) to $730 from $788, Johnson & Johnson (JNJ) to $284 from $283, and Eli Lilly (LLY) to $1,347 from $1,344.Shares of Biogen, Amgen, Gilead, AbbVie, Moderna, BioNTech, Regeneron, Johnson & Johnson, and Eli Lilly were down 2%, 0.1%, 0.8%, 0.4%, 7%, 1.9%, 1.9%, 0.4%, and 0.5% respectively, in Wednesday trading.Price: $201.67, Change: $-4.03, Percent Change: -1.96%
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1.4%.In corporate news, Vertex Pharmaceuticals (VRTX) agreed to buy endocrine disease drugmaker Crinetics Pharmaceuticals (CRNX) for a total equity value of about $10 billion. Crinetics shares jumped 98%, and Vertex was down 1.2%.Eli Lilly (LLY) Canada said Tuesday that Health Canada has approved Mounjaro for pediatric patients aged 10 to 17 with type 2 diabetes. Lilly shares rose 2.7%.Vera Therapeutics' (VERA) Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement. Vera Therapeutics shares jumped by more than 7%.AstraZeneca (AZN) has signed an agreement to access Helix's genomic datasets to support research for drug discovery and development, Helix said Tuesday. AstraZeneca shares added 1.4%.
Carmen Bozic, Chief Medical Officer and Executive Vice President, on June 15, 2026, sold 4,062 shares in Vertex Pharmaceuticals (VRTX) for $1,827,900. Following the Form 4 filing with the SEC, Bozic has control over a total of 16,953 common shares of the company, with 16,953 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000235/xslF345X05/wk-form4_1781727153.xml
Carmen Bozic, Chief Medical Officer and Executive Vice President, on June 05, 2026, sold 1,745 shares in Vertex Pharmaceuticals (VRTX) for $785,250. Following the Form 4 filing with the SEC, Bozic has control over a total of 21,015 common shares of the company, with 21,015 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000233/xslF345X05/wk-form4_1781036661.xml
Carmen Bozic, Executive Vice President and Chief Medical Officer, on May 29, 2026, sold 1,974 shares in Vertex Pharmaceuticals (VRTX) for $888,300. Following the Form 4 filing with the SEC, Bozic has control over a total of 22,760 common shares of the company, with 22,760 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000228/xslF345X05/wk-form4_1780430661.xml
Vertex Pharmaceuticals (VRTX) said Thursday that Health Canada accepted for review its new drug submission for suzetrigine for the treatment of moderate-to-severe acute pain in adults.Suzetrigine is an investigational, oral, selective NaV1.8 pain signal inhibitor and represents a new class of oral pain medicine that is neither an opioid nor a nonsteroidal anti-inflammatory drug, the company said.The company added that it intends for the regulatory review of suzetrigine to be part of an aligned review with Canadian Health Technology Assessment Organizations, including Canada's Drug Agency and Quebec's Institut national d'excellence en sante et en services sociaux.Suzetrigine was approved by the US Food and Drug Administration under the brand name Journavx in January 2025 and received breakthrough therapy, fast track and priority review designations, the biotechnology company said.Price: $432.66, Change: $+2.22, Percent Change: +0.52%
Carmen Bozic, Chief Medical Officer and Executive Vice President, on May 15, 2026, sold 1,354 shares in Vertex Pharmaceuticals (VRTX) for $613,971. Following the Form 4 filing with the SEC, Bozic has control over a total of 24,734 common shares of the company, with 24,734 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000225/xslF345X05/wk-form4_1779221059.xml
Joy Liu, Executive Vice President and Chief Legal Officer, on May 01, 2026, sold 1,104 shares in Vertex Pharmaceuticals (VRTX) for $469,222. Following the Form 4 filing with the SEC, Liu has control over a total of 20,729 common shares of the company, with 20,729 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/875320/000087532026000183/xslF345X05/wk-form4_1778015480.xml
Vertex Pharmaceuticals' (VRTX) management remains confident in its emerging renal franchise, suggesting it could rival or even exceed its cystic fibrosis franchise eventually, Oppenheimer said in a Tuesday note.The strong uptake of Alyftrek is encouraging, and Oppenheimer expects continued growth in US and international markets, driven by adoption among treatment-naive patients, those who previously discontinued cystic fibrosis therapy, and patients who switched to Alyftrek, according to the note.Uptake of Alyftrek among younger patients and more access in Europe should support long-term growth, according to the note. For Journavx, management remains confident in tripling total scripts in 2026, the brokerage said.Management remains confident in Pove's profile, and the recent submission completion for Pove suggests a potential FDA decision by year-end, according to the note.Oppenheimer said Inaxaplin represents the next key catalyst, with the phase 2 AMPLIFIED study readout now expected in H2, compared with the prior mid-2026 guidance.Oppenheimer maintained an outperform rating on Vertex Pharmaceuticals with a price target of $600.Price: $423.92, Change: $-5.93, Percent Change: -1.38%
US equity futures were higher pre-bell Tuesday as traders kept a close watch on the potential re-escalation of hostilities in the Middle East.Dow Jones Industrial Average futures were 0.4% higher, S&P 500 futures were up 0.5%, and Nasdaq futures were 0.8% higher.The UAE said that it was attacked by Iranian drones and missiles, while the US said it sank Iranian boats in the Strait of Hormuz.President Donald Trump had said that the US would help guide vessels stranded in the Persian Gulf. In a post Monday on Truth Social, he said that a South Korean cargo ship had been damaged by Iran, but the US had shot down seven Iranian small boats."Other than the South Korean Ship, there has been, at this moment, no damage going through the Strait," Trump said.Traders digested the latest round of earnings, with Palantir Technologies (PLTR) and Vertex Pharmaceuticals (VRTX) reporting higher Q1 adjusted earnings and revenue. HSBC (HSBC) also posted an increase in Q1 earnings and revenue.Oil prices were lower, with front-month global benchmark North Sea Brent crude down 2.2% at $111.91 per barrel and US West Texas Intermediate crude 3.2% lower at $103.04 per barrel.The US international trade deficit widened to $60.31 billion in March from a $57.78 billion gap in February, compared with a $61.0 billion gap expected in a survey compiled by Bloomberg as of 7:40 am ET.The S&P Global purchasing managers' index composite final report for April, due at 9:45 am ET, is seen reporting 52.1 versus 52.0 previously.March new home sales report, due at 10 am ET, is expected to post a 652,000 annual rate. The April Institute for Supply Management's services index is projected at 53.7 versus 54.0 previously. March job openings from the US Department of Labor's Job Openings and Labor Turnover Survey are expected to come in at 6.850 million compared with 6.882 million in the prior month.Federal Reserve Vice Chair for Supervision Michelle Bowman and Fed Governor Michael Barr are due to speak today.In other world markets, Japan's Nikkei and China's Shanghai Composite were closed due to public holidays. Hong Kong's Hang Seng ended 0.8% lower. The UK's FTSE 100 was down 1.4%, and Germany's DAX index was 1.6% higher in Europe's early afternoon session.In equities, Intel (INTC) shares were up 3.8% after Bloomberg reported the Apple (AAPL) has held early discussions with the company and Samsung Electronics on producing key device processors in the US. Anheuser-Busch InBev (BUD) stock was up 6.6% after the company reported fiscal Q1 underlying earnings and revenue that beat analysts' estimates. Pinterest (PINS) shares were up 18% after the company posted higher Q1 non-GAAP earnings and revenue that beat analysts' consensus.On the losing side, Palantir and HSBC shares were down 1.3% and 3.9%, respectively, after they reported Q1 financial results. Shopify (SHOP) stock was 5.9% lower after the company reported a Q1 loss while analysts expected earnings.
US equity futures were higher pre-bell Tuesday as traders kept a close watch on the potential re-escalation of hostilities in the Middle East.Dow Jones Industrial Average futures were 0.3% higher, S&P 500 futures were up 0.4%, and Nasdaq futures were 0.6% higher.The UAE said that it was attacked by Iranian drones and missiles, while the US said it sank Iranian boats in the Strait of Hormuz.President Donald Trump had said that the US would help guide vessels stranded in the Persian Gulf. In a post Monday on Truth Social, he said that a South Korean cargo ship had been damaged by Iran, but the US had shot down seven Iranian small boats."Other than the South Korean Ship, there has been, at this moment, no damage going through the Strait," Trump said.Traders digested the latest round of earnings, with Palantir Technologies (PLTR) and Vertex Pharmaceuticals (VRTX) reporting higher Q1 adjusted earnings and revenue. HSBC (HSBC) also posted a Q1 increase in earnings and revenue.Oil prices were lower, with front-month global benchmark North Sea Brent crude down 1.6% at $112.67 per barrel and US West Texas Intermediate crude 2.4% lower at $103.94 per barrel.The international trade in goods report, scheduled for release at 8:30 am ET, is expected to post a deficit widening to $61 billion from $57.3 billion in the prior month, according to estimates compiled by Bloomberg. The purchasing managers' index composite final report for April, due at 9:45 am ET, i is seen coming in at 52.1 versus 52.0 previously.March new home sales, due at 10 am ET, is seen coming in at a 652,000 annual rate. The April Institute for Supply Management's services index is projected at 53.7 versus 54.0 previously. March job openings from the Department of Labor's Job Openings and Labor Turnover Survey are expected to come in at 6.850 million compared with 6.882 million in the prior month.Federal Reserve Vice Chair for Supervision Michelle Bowman is slated to speak at 10 am, while Fed Governor Michael Barr speaks at 12:30 pm.
Showing 1-20 of 23
